NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
|
|
- Ilene Howard
- 6 years ago
- Views:
Transcription
1 NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. WHO CLASSIFICATION OF NON-HODGKIN LYMPHOMA **SUMMARY DOCUMENT FOCUSES ON DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)**
2 A) PUBLIC HEALTH EPIDEMIOLOGY - Incidence: Accounts for 30% of all NHLs in the developed world - Mortality: Approximately 66% will survive for 5 years or more after diagnoses RISK FACTORS - Genetic: Male predominance, Caucasians have higher rates familial aggregation of patients with DLBCL observed - Other: HIV, Richter s transformation from CLL (or transformation from other indolent non-hodgkin lymphomas) PREVENTION & SCREENING - Assess patients with established CLL for Richter s transformation B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS - Common Symptoms: Rapidly enlarging symptomatic mass, commonly nodal enlargement in neck or abdomen. Systemic B symptoms (fever, weight loss, drenching night sweats) - Common Signs: Lymph node enlargement on lymphoid survey (examination of Waldeyer s ring, head and neck, axillary and chest, abdomen, inguinal regions). Signs related to mass and compression of nearby structures (ie) SVC syndrome if mediastinal mass. - Common Presentations: Extranodal involvement in up to 40%. Extranodal sites include GI tract, bone, testis, spleen, Waldeyer ring, and salivary gland. Bone marrow involvement in 11-27% or cases and can be discordant low grade B-cell lymphoma. INVESTIGATIONS - Laboratory: Lymph node pathology (excisional preferred), CBC and differential, creatinine, electrolytes, liver enzymes, LDH, calcium, viral screen (Hepatitis B surface antibody, Hepatitis B surface antigen, Hepatitis C antibody, HIV serology) - Diagnostic Imaging: PET/CT of neck/chest/abdomen/pelvis. Echo or MUGA for baseline cardiac function prior to anthracycline. - Diagnostic Procedures: Bone marrow biopsy and aspirate not required if staging PET/CT performed. Lumbar puncture (CSF for flow cytometry) and MRI Brain with gadolinium if suspect CNS involvement. PATHOLOGY & MOLECULAR BIOLOGY - Common Histology: Large B lymphoid cell morphology. Immunohistochemistry CD20+, CD19+, CD10+/-, bcl6+ (60-90%), MUM1+ (35-65%). - Common Extranodal Sites: CNS (leptomeningeal), testicular, skin - Relevant Molecular Biology: Evaluation of c-myc, bcl-2, and bcl-6 status (by FISH or immunohistochemistry). Evaluation of cell of origin by gene expression profile analysis (if available). Using this information, an individual case may be further subclassified as Germinal center B cell (GCB) DLBCL, Activated B cell (ABC) DLBCL (or non-gcb DLBCL), or Double hit DLBCL. For example: o GCB type: CD10+, bcl6+, MUM1- o ABC type: CD10 -, bcl6-, MUM1+ o Double hit: c-myc translocation + gene rearrangement of bcl-2
3 STAGING - Ann Arbor Staging: Stage Description I Involvement of a single lymph node region or a single extranodal site II Involvement of two or more lymph node regions on the same side of the diaphragm III Involvement of lymph node regions on both sides of the diaphragm IV Diffused/disseminated involvement of one or more extra lymphatic organs or tissues with or without associated lymph node involvement Other B Symptoms: absence (A) or presence (B) or fever >38.5 C, drenching night sweats, and/or unexplained weight loss of >10% body weight in past 6 months E: Extranodal disease X: Bulky disease. Defined as mediastinal mass >1/3 thoracic diameter or any nodal mass >10cm in maximal diameter PROGNOSIS - International Prognostic Factor Index (IPI) o Dependent on five prognostic factors: Age >60, Performance Status 2, elevated LDH, Extranodal Site >1, Stage III/IV o Revised IPI for DLBCL following RCHOP chemotherapy Factors # of Factors 4 year PFS 4 year OS Age > % 95% ECOG 2 Elevated LDH % 79% Extranodal Site >1 Stage III/IV % 55% C) TREATMENT NON-BULKY LIMITED STAGE DLBCL - Bottom Line General Approach: Nonbulky (<10cm), limited stage (Ann Arbor Stage I or II) DLBCL are treated with combined modality therapy consisting of R-CHOP chemoimmunotherapy (Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone) and involved field radiation therapy (IFRT). Interim PET/CT to determine post therapy IFRT. - Also acceptable R-CHOP x 3-4 cycles + IFRT if no stage adjusted IPI factors; R-CHOP x 6 cycles (with or without IFRT for local control) if >=1 stage adjusted IPI factors
4 - Important Phase III Clinical Trials: Studies involving addition of Rituximab CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-b-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh et al. Lacet Oncol. 2006; 7(5): 379. Mechanism of Action of Experimental Drug 6 cycles CHOP-like (CHOP, CHOEP, MACOP-B) vs 6 cycles R-CHOP Rituximab: anti-cd20 monoclonal antibody Event free survival Inclusion: age 18-60, no IPI risk factors, stage II-IV disease, or stage I disease with bulky disease. 824 patients RCHOP vs CHOP-like 3yr EFS: 79% vs 59% 6yr PFS: 80.2% vs 63.9% 6yr OS: 90.1% vs 80% Rituximab added to 6 cycles of CHOP is an effective treatment for young patients with good prognosis DLBCL Studies involving radiotherapy for localized DLBCL Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-hodgkin s lymphoma. SWOG 8736 trial Miller et al. NEJM. 1998;339(1):21.
5 8 cycles CHOP vs 3 cycles CHOP + IFRT PFS, OS, Toxic effects Localized, intermediate- or high-grade NHL (75% were DLBCL) 401 patients CHOP + IFRT vs CHOP alone 5yr PFS: 77% vs 64% 5yr OS: 82% vs 72% Life threatening toxic effects: 61/200 vs 80/201 Toxicity LV function decreased in 7 pts with CHOP alone vs no cardiac events in those receiving CHOP + IFRT 3 cycles CHOP + IFRT are superior to 8 cycles of CHOP alone for the treatment of localized intermediate- and high-grade non-hodgkin s lymphoma. Other comments A reanalysis of this showed that the OS curves overlapped in long-term follow-up with a continuous pattern of relapse outside of radiation field for people who got abbreviated chemo + rads. Only those patients with no IPI risks did well with abbreviated chemo + rads CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Group d Etude des Lymphomes de l Adulte. GELA LNH 93-4 trial. Bonnet et al. JCO. 2007; 25(7): cycles CHOP + IFRT vs 4 cycles CHOP alone EFS Age >60yo with localized stage I or II aggressive lymphoma with no adverse prognostic factors of the IPI 576 patients CHOP + IFRT vs CHOP alone 5yr EFS: 64% vs 61% 5yr OS: 68% vs 72% CHOP plus radiotherapy did not provide any advantage over CHOP alone for the treatment of low risk localized aggressive lymphoma in elderly patients. However, patients who received IFRT had a lower rate of relapse at the site of initial disease ADVANCED STAGE DLBCL - Bottom Line General Approach: Advanced stage (Ann Arbor Stage III or IV) or bulky disease (>10cm) DLBCL are treated with combined modality therapy consisting of R-CHOP 6 cycles +/- IFRT (if post therapy PET/CT positivity). Consider autologous stem cell transplant (ASCT) if high IPI risk factors (>3)
6 - Important Phase III Clinical Trials: Studies involving addition of Rituximab Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial. RICOVER-60 Pfreundschuh et al. Lancel Oncol. 2008;9(2): or 8 cycles R-CHOP-14 vs 6 or 8 cycles CHOP-14 EFS Elderly age 61-80yo 1222 patients 6 CHOP-14 vs 8 CHOP-14 vs 6 RCHOP-14 vs 8 RCHOP-14 3yr EFS: 47.2% vs 53% vs 66.5% vs 63.1% 3yr OS: 67.7% vs 66% vs78.1% vs 72.5% 6 RCHOP-14 improved EFS, PFS and OS compared to 6 CHOP-14. Of the four regiments assessed in this study, 6 cycles RCHOP-14 is the preferred treatment for elderly patients. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. GELA LNH-98.5 Coiffier et al. NEJM. 2002;346(4): cycles CHOP vs 8 cycles R-CHOP EFS Elderly age with untreated DLBCL 399 patients RCHOP vs CHOP Rate of CR: 76% vs 63% 2yr EFS: 57% vs 38% 2yr OS: 70% vs 57% The addition of rituximab to the CHOP regiment increases the complete response rate and prolongs event free and overall survival in elderly patients with DLBCL without a clinically significant increase in toxicity Studies involving intensity of RCHOP therapy Dose-dense rituximab-chop compared with standard rituximab-chop in elderly patients with diffuse large B-cell lymphoma:a randomised phase 3 trial. GELA LNH03-6B study Delarue et al. Lancet Oncol. 2013;14(6): 525. Inclusion 8 cycles RCHOP every 14 days vs 8 cycles RCHOP every 21 days Event free survival Inclusion: age and at least one adverse prognostic factor 602 patients RCHOP14 vs RCHOP21 3yr EFS: 56% vs 60% Grade 3-4 neutropenia: 74% vs 64% Red blood cell transfusion: 47% vs 31% In elderly patients with DLBCL, a 2-week RCHOP regimen did not improve efficacy compared with the 3-week standard schedule.
7 RELAPSED DLBCL - Bottom Line General Approach: If transplant eligible, treat with R-DICEP or R-GDP followed by high dose therapy/asct. If not transplant eligible, treat with palliative therapy (such as decreased GDP, CEPP, PEPC, or IFRT). OTHER TREATMENT CONSIDERATIONS FOR DLBCL - Cardiac: anthracycline induced cardiomyopathy or arrhythmia, change doxorubicin to etoposide. - Liver/Increased Bilirubin: Dose reduce doxorubicin and vincristine. - Hepatitis B: Treat with Lamivudine or Tenofovir - Neuropathy: dose reduce or omit vincristine - HIV: HAART therapy, caution with rituximab if CD4 count less 50 - Diabetes: Prednisone induced - BPH/Urinary Retention: Cyclophosphamide induced hemorrhagic cystitis - CNS Prophylaxis: No role for intrathecal chemo. Consider high dose methotrexate if high risk features such as involvement of sinuses, testes, or adrenals. (and dual translocation) - GCSF Support: Consider secondary prophylaxis if develop febrile neutropenia during therapy. - Advanced stage GCB type DLBCL: standard 6 cycles R-CHOP - Advanced stage ABC type DLBCL: consider enrollment in clinical trial evaluating incorporation of novel agents (ie) RCHOP plus lenalidomide, or ibrutinib, or bortezomib. -Dual translocation consider enrolment in trial or consider R-EPOCH (based on cohort/case series data suggesting poor outcomes with R-CHOP) D) REFERENCES 1. Alberta Health Services Guidelines 2. UptoDate 3. Canadian Cancer Society 4. Odette Cancer Centre Guidelines
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationJournal of American Science 2016;12(6)
Role of reduced dose CHOP with Rituximab plus involved field radiotherapy in treatment of early stage diffuse large B cell lymphoma in elderly patients Lobna A. Abdelaziz 1, Reham A. Salem 1, Nabila Hefzi
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationTraitement des lymphomes diffus à grandes cellules B
Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma AA Cancer Centre All patients with a potential or confirmed lymphoproliferative
More informationLYMPHOMA IN OLDER PEOPLE. Ama Rohatiner, St. Bartholomew s Hospital, Londonj
LYMPHOMA IN OLDER PEOPLE Ama Rohatiner, St. Bartholomew s Hospital, Londonj LYMPHOMA IN OLDER PEOPLE PERSPECTIVES HALF OF ALL NEWLY-DIAGNOSED PTS. WITH LYMPHOMA ARE >60 MAY REQUIRE DIFFERENT MANAGEMENT
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationPrognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationDiffuse large B-cell lymphomas. G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013
Diffuse large B-cell lymphomas G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013 Case A 72-year-old previously healthy man presented with acute abdominal pain and a 15 kg weight loss. Positron
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationACCME/Disclosures. DLBCL, NOS from the clinician perspective. Diffuse large B cell lymphoma
, NOS from the clinician perspective John P. Leonard, M.D. Weill Cornell Medicine New York Presbyterian Hospital ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationNICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52
Non-Hodgkin s lymphoma: diagnosis and management NICE guideline Published: 20 July 2016 nice.org.uk/guidance/ng52 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationT-cell Lymphomas Biology and Management
T-cell Lymphomas Biology and Management March-27-2017 Outline Epidemiology Initial Work-up International Prognostic Index Treatment of Diffuse Large B-cell Lymphoma: -Limited Stage -Advanced Stage Frontline:
More informationCNS Lymphoma. Las Vegas-- March 10-12, 2016
CNS Lymphoma Las Vegas-- March 10-12, 2016 Frequency 3% of primary cerebral tumors 1% of NHLs Recent developments and controversies in PCNSL Hottinger et al Current Opinion in Oncology Vol 27 No. 6 November
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationFollicular and Diffuse Large B-Cell Lymphoma - Studies of Primary Treatment and Prognostic Factors
Follicular and Diffuse Large B-Cell Lymphoma - Studies of Primary Treatment and Prognostic Factors Szekely, Elisabeth Published: 2018-01-01 Document Version Publisher's PDF, also known as Version of record
More informationOriginal Article. Introduction
Original Article Radiat Oncol J 217;35(4):317-324 https://doi.org/1.3857/roj.217.451 pissn 2234-19 eissn 2234-3156 Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck
More informationNCCP Chemotherapy Protocol. CHOEP Therapy 21 days. Treatment of T-cell Non-Hodgkins Lymphoma C a
CHOEP Therapy 21 days INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of T-cell Non-Hodgkins Lymphoma C85 00396a ELIGIBILTY: Indication as above Age < 60 years Adequate haematological, renal
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationPathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine
Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine Xianhui Liu 1, 2#, a, Xiaona Guo 3#, b and Chunsheng Yan 3, c 1 Henan Province Hospital of
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationDurable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit DLBCL treated with lenalidomide monotherapy Running head: Durable remission with lenalidomide in CNS relapse
More informationNAACCR Webinar Series 1
COLLECTING CANCER DATA: HEMATOPOIETIC AND LYMPHOID NEOPLASMS Jim Hofferkamp, CTR (jhofferkam@naaccr.org) Shannon Vann, CTR (svann@naaccr.org) Q&A Please submit all questions concerning webinar content
More informationLINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES.
Congreso Nacional SEAP 2013. LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES. Santiago Montes Moreno Servicio de Anatomía Patológica, HUMV
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationACR Appropriateness Criteria Diffuse Large B-Cell Lymphoma EVIDENCE TABLE
. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 008;():38-399.. Juweid ME, Stroobants S, Hoekstra OS, et al. Use
More informationLymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.
Scan for mobile link. Lymphoma Lymphoma is a cancer that develops in the white blood cells of the lymphatic system. Symptoms may include enlarged lymph nodes, unexplained weight loss, fatigue, night sweats
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More information